Quantitative Ultrasound Detects Bone Changes Following Bone Marrow Transplantation in Pediatric Subjects with Hematological Diseases: a Longitudinal Study

Overview

Journal J Endocrinol Invest

Publisher Springer

Specialty Endocrinology

Date 2010 Jan 27

PMID 20101099

Citations 1

Authors

N Di Iorgi

E Calandra

A Secco

F Napoli

A Calcagno

M Ghezzi

C Frassinetti

F De Terlizzi

G Giorgiani

F Locatelli

M Maghnie

Affiliations

Soon will be listed here.

Abstract

Background: Bone marrow transplantation (BMT) is associated with bone morbidity. We investigated bone status with quantitative ultrasound (QUS) in pediatric patients with hematological diseases prior to and up to 3 yr following BMT.

Methods: Phalangeal QUS measures for amplitude- dependent speed of sound (Ad-SoS) and bone transmission time (BTT) were obtained in 40 hematological patients (25 with malignant, 15 with non-malignant disease; 9.7+/-4.9 yr) before BMT and 6, 12, 24, and 36 months after BMT. Bone parameters were expressed as Z-scores based on age-sex-matched normal controls.

Results: Mean Ad-SoS and BTT Z-scores were normal before BMT and reduced at 36 months (analysis of variance: p=0.0542 and p=0.0233). Ad-SoS and BTT Z-scores remained relatively stable in the first 6 months after BMT and then progressively decreased reaching a plateau at 12-36 months. In non-malignant patients, BTT Z-score decreased at 6-12 months (p=0.029) and subsequently increased, while in malignant patients BTT Z-score showed a decrease at 12-24 months. Pre-pubertal subjects displayed a drop of BTT Z-Score values at both 12 (p=0.023) and 36 months after BMT (p=0.049), while BTT Z-score remained relatively unchanged in pubertal subjects. Early impairment of BTT Z-score was found in patients who suffered acute graft versus host disease (GVHD) compared to patients without this clinical condition; BTT Z-score was lower at 36 months (p=0.045).

Conclusions: Longitudinal assessment by QUS of pediatric BMT survivors evidenced that bone status is mildly affected up to 36 months after BMT, mainly in malignant patients, in pre-pubertal subjects at BMT and in patients who suffered acute GVHD.

Citing Articles

Bone loss and vitamin D deficiency in children undergoing hematopoietic cell transplantation.

Bechard L, Gordon C, Feldman H, Venick R, Gura K, Guinan E Pediatr Blood Cancer. 2015; 62(4):687-92.

PMID: 25630874 PMC: 4743025. DOI: 10.1002/pbc.25370.

References

Hamiwka L, Hanna M, Midgley J, Wade A, Grisaru S . Areal and volumetric bone mineral density changes after renal transplantation in children: a longitudinal study. Transplant Proc. 2008; 40(5):1404-6. DOI: 10.1016/j.transproceed.2008.03.098. View

Stern J, Sullivan K, Ott S, Seidel K, Fink J, Longton G . Bone density loss after allogeneic hematopoietic stem cell transplantation: a prospective study. Biol Blood Marrow Transplant. 2001; 7(5):257-64. DOI: 10.1053/bbmt.2001.v7.pm11400947. View

Valta H, Jalanko H, Holmberg C, Helenius I, Makitie O . Impaired bone health in adolescents after liver transplantation. Am J Transplant. 2007; 8(1):150-7. DOI: 10.1111/j.1600-6143.2007.02015.x. View

Baroncelli G, Federico G, Vignolo M, Valerio G, Del Puente A, Maghnie M . Cross-sectional reference data for phalangeal quantitative ultrasound from early childhood to young-adulthood according to gender, age, skeletal growth, and pubertal development. Bone. 2006; 39(1):159-73. DOI: 10.1016/j.bone.2005.12.010. View

Enright H, Haake R, Weisdorf D . Avascular necrosis of bone: a common serious complication of allogeneic bone marrow transplantation. Am J Med. 1990; 89(6):733-8. DOI: 10.1016/0002-9343(90)90214-x. View

Tanner J, Whitehouse R . Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. Arch Dis Child. 1976; 51(3):170-9. PMC: 1545912. DOI: 10.1136/adc.51.3.170. View

Movsowitz C, Epstein S, Fallon M, Ismail F, Thomas S . Cyclosporin-A in vivo produces severe osteopenia in the rat: effect of dose and duration of administration. Endocrinology. 1988; 123(5):2571-7. DOI: 10.1210/endo-123-5-2571. View

Bhatia S, Ramsay N, Weisdorf D, Griffiths H, Robison L . Bone mineral density in patients undergoing bone marrow transplantation for myeloid malignancies. Bone Marrow Transplant. 1998; 22(1):87-90. DOI: 10.1038/sj.bmt.1701275. View

Taskinen M, Kananen K, Valimaki M, Loyttyniemi E, Hovi L, Saarinen-Pihkala U . Risk factors for reduced areal bone mineral density in young adults with stem cell transplantation in childhood. Pediatr Transplant. 2006; 10(1):90-7. DOI: 10.1111/j.1399-3046.2005.00405.x. View

10.

Chae Y, Kim J, Moon J, Kim S, Lee S, Kim Y . Pilot study on the use of zoledronic acid to prevent bone loss in allo-SCT recipients. Bone Marrow Transplant. 2009; 44(1):35-41. DOI: 10.1038/bmt.2008.414. View

11.

Legault L, Bonny Y . Endocrine complications of bone marrow transplantation in children. Pediatr Transplant. 1999; 3(1):60-6. DOI: 10.1034/j.1399-3046.1999.00009.x. View

12.

Di Iorgi N, Muratori T, Secco A, Napoli F, Fratangeli N, Terlizzi F . Quantitative ultrasound detects bone impairment after bone marrow transplantation in children and adolescents affected by hematological diseases. Bone. 2008; 43(1):177-182. DOI: 10.1016/j.bone.2008.03.018. View

13.

Socie G, Cahn J, Carmelo J, Vernant J, Jouet J, Ifrah N . Avascular necrosis of bone after allogeneic bone marrow transplantation: analysis of risk factors for 4388 patients by the Société Française de Greffe de Moëlle (SFGM). Br J Haematol. 1997; 97(4):865-70. DOI: 10.1046/j.1365-2141.1997.1262940.x. View

14.

Nysom K, Holm K, Michaelsen K, Hertz H, Jacobsen N, Muller J . Bone mass after allogeneic BMT for childhood leukaemia or lymphoma. Bone Marrow Transplant. 2000; 25(2):191-6. DOI: 10.1038/sj.bmt.1702131. View

15.

Socie G, Clift R, Blaise D, Devergie A, Ringden O, Martin P . Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. Blood. 2001; 98(13):3569-74. DOI: 10.1182/blood.v98.13.3569. View

16.

Tauchmanova L, Colao A, Lombardi G, Rotoli B, Selleri C . Bone loss and its management in long-term survivors from allogeneic stem cell transplantation. J Clin Endocrinol Metab. 2007; 92(12):4536-45. DOI: 10.1210/jc.2006-2870. View

17.

Lackner H, Benesch M, Moser A, Smolle-Juttner F, Linhart W, Raith J . Aseptic osteonecrosis in children and adolescents treated for hemato-oncologic diseases: a 13-year longitudinal observational study. J Pediatr Hematol Oncol. 2005; 27(5):259-63. DOI: 10.1097/01.mph.0000163215.37147.13. View

18.

Stern J, Chesnut 3rd C, Bruemmer B, Sullivan K, Lenssen P, Aker S . Bone density loss during treatment of chronic GVHD. Bone Marrow Transplant. 1996; 17(3):395-400. View

19.

Baker K, Gurney J, Ness K, Bhatia R, Forman S, Francisco L . Late effects in survivors of chronic myeloid leukemia treated with hematopoietic cell transplantation: results from the Bone Marrow Transplant Survivor Study. Blood. 2004; 104(6):1898-906. DOI: 10.1182/blood-2004-03-1010. View

20.

Mandel K, Atkinson S, Barr R, Pencharz P . Skeletal morbidity in childhood acute lymphoblastic leukemia. J Clin Oncol. 2004; 22(7):1215-21. DOI: 10.1200/JCO.2004.04.199. View